Vertaling van "fnc was granted and " (Nederlands → Frans) :

In the SDNY, Novartis AG’s motion to dismiss all cases pending there based on the doctrine of forum non conveniens (FNC) was granted and the case was dismissed on July 2, 2010.
En s’appuyant sur la doctrine «forum non conveniens (FNC)», Novartis a obtenu que le SDNY rejette toutes les plaintes et sa décision a été communiquée le 2 juillet 2010.

In the SDNY, Novartis AG’s motion to dismiss all cases pending there based on FNC was granted and the case was dismissed on July 2, 2010.
En s’appuyant sur la même doctrine, Novartis a obtenu que le SDNY rejette toutes les plaintes déposées devant lui, décision communiquée le 2 juillet 2010.

Novartis AG’s motion to dismiss the consolidated Texas state court actions based on the doctrine of forum non conveniens (FNC) was filed on June 30, 2010.
En se basant sur la doctrine dite « forum non conveniens (FNC) », Novartis AG a demandé, le 30 juin 2010, le rejet des plaintes consolidées devant les tribunaux du Texas.

Novartis AG’s motion to dismiss the consolidated Texas state court actions based on FNC was filed on June 30, 2010, and is still pending.
En se basant sur la doctrine FNC, Novartis AG a demandé, le 30 juin 2010, le rejet des plaintes consolidées devant les tribunaux du Texas; cette requête est encore en suspens.

Extavia (USD 26 million), for patients with relapsing forms of multiple sclerosis (MS), was first launched in the European Union in early 2009 and is now available in more than 15 countries, including the US where it was launched recently after regulatory approval was granted in August 2009.
Extavia (USD 26 millions), pour les malades atteints de formes cycliques de sclérose en plaques (SEP), a été commercialisé d’abord dans l’Union européenne début 2009.

Afinitor (USD 12 million), an oral inhibitor of the mTOR pathway, was launched in the US after regulatory approval was granted in March as the first therapy for patients with advanced renal cell carcinoma (kidney cancer) after failure of treatment with sunitinib or sorafenib.
Afinitor (USD 12 millions), inhibiteur par voie orale de la voie mTOR, a été lancé aux Etats-Unis après avoir reçu, en mars, son homologation en tant que traitement du carcinome avancé des cellules rénales (cancer du rein) après échec d’un traitement par sunitinib ou sorafenib.

On 23 December 2005, approval was granted by the Council of Ministers for the establishment of an autonomous medicines agency: the Federal Agency for Medicines and Health Products or FAMHP.
On 23 December 2005, approval was granted by the Council of Ministers for the establishment of an autonomous medicines agency: the Federal Agency for Medicines and Health Products or FAMHP.

It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.
It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.

In addition to the daily activities (inspections, granting of licences/authorisations/certificates, RAS) the Production & Distribution Department also focused efforts in 2008 on gradually solving the backlog of Dutch language establishment applications and transfer applications for retail pharmacies. Additionally, the backlog in respect of raw materials used by retail pharmacies was also tackled.
In addition to the daily activities (inspections, granting of licences/authorisations/certificates, RAS) the Production & Distribution Department also focused efforts in 2008 on gradually solving the backlog of Dutch language establishment applications and transfer applications for retail pharmacies. Additionally, the backlog in respect of raw materials used by retail pharmacies was also tackled.

Malaria kills a child under age five every 30 seconds in Africa Only 10% of R&D funds are used for research into 90% of the world’s health problems The NITD was granted USD 20 million in 2006 by the Wellcome Trust, the Singapore Economic Development Board and Medicines for Malaria Venture to initiate joint research on malaria Leprosy has dropped by over 90% since 1985 Deliveries for Coartem have climbed from four million treatments in 2004 to over 60 million in 2006
En Afrique, la malaria tue un enfant de moins de cinq ans toutes les 30 secondes Seuls 10% des fonds consacrés à la recherche sont investis dans les maladies qui représentent 90% des problèmes de santé dans le monde En 2006, l’Institut Novartis pour les maladies tropicales a obtenu du Wellcome Trust, du Singapore Economic Development Board et de Medicines for Malaria Venture USD 20 millions pour initier un programme commun de recherche sur la malaria Depuis 1985, la lèpre a diminué de plus de 90% Entre 2004 et 2006, les livraisons de Coartem sont passées de 4 millions à plus de 60 millions de traitements